Proteinmaxxing and Weight-Loss Drugs Could Drive Up Infant Formula Prices

The surging popularity of the 'proteinmaxxing' trend and the widespread adoption of GLP-1 based weight-loss medications have significantly increased demand for whey protein, a vital ingredient in infant formula production. Experts warn that this heightened demand could exert upward pressure on infant formula prices. The 'proteinmaxxing' trend, which sees consumers attempting to consume as much protein as possible, has gained momentum over the past year as health professionals emphasize the benefits of protein.

A key factor behind this surge in whey protein demand is the growing use of GLP-1 class weight-loss drugs. Individuals using these medications are increasingly seeking protein-rich foods to preserve muscle mass while losing weight. This has led to intensified interest in concentrated whey protein, commonly found in protein shakes and bars. According to Expana, a global market intelligence platform, the price of whey protein concentrate 80 (WPC 80), containing 80% pure protein, increased significantly from €11,733 per metric tonne in July 2025 to €25,875 by July 2026.

This situation is forcing infant formula manufacturers to contend with higher input costs. Industry insiders caution that consumers may soon feel the impact of this rising demand. Whey protein is a crucial ingredient in infant formula, used to mimic human breast milk by adjusting protein ratios and enhancing digestibility. Data from the UK's Office for National Statistics (ONS) indicates that the average price of baby formula has already risen by 4.8% over the past year, with a 750g box now costing £12.11, up from £11.55 a year earlier. In response to these escalating costs, many manufacturers have reformulated their recipes, increasing the use of demineralized whey powder 90 (D90).

This dynamic in the whey protein market reflects a broader trend of increased demand for protein-focused products across the global food industry. Euromonitor International research shows that retail sales of high-protein foods, drinks, and supplements exceeded $3 trillion in 2025, with global protein demand projected to grow by 11% between 2024 and 2029. New US federal dietary guidelines, which recommend higher daily protein intake, also support this trend. This wider context explains why whey protein, once considered a byproduct of cheese production, has evolved into a strategically valuable commodity.

Market analysts suggest that current high whey protein prices are becoming economically unsustainable at existing retail price levels. Further consumer price increases are anticipated unless raw material costs ease. If the global adoption of GLP-1 medications continues to rise, supply constraints are likely to persist, maintaining pressure on prices. This situation is also drawing the attention of regulatory bodies that closely monitor competition and pricing in the infant formula market, as the Competition and Markets Authority (CMA) previously investigated high prices and lack of competition in the UK infant formula market. In the coming period, both manufacturers' cost management strategies and the trajectory of global protein demand will be closely watched for their impact on infant formula prices.